Revolution Medicines
RVMD
Revolution Medicines (RVMD) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$3.06
- EPS estimate
- −$2.04
- EPS surprise
- −49.81%
- Revenue surprise
- −100.00%
- Revenue
- $0.00
- Revenue estimate
- $1.8M
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$2.04 | −$3.06 | −49.81% | $0.00 | SEC |
| Q1 2026 | May 6, 2026 | −$1.84 | −$2.29 | −24.75% | $0.00 | SEC |
| Q4 2025 | Feb 25, 2026 | −$1.58 | −$1.86 | −17.63% | $0.00 | SEC |
| Q3 2025 | Nov 5, 2025 | −$1.42 | −$1.61 | −13.29% | $0.00 | SEC |
| Q2 2025 | Aug 6, 2025 | −$1.14 | −$1.31 | −15.11% | $0.00 | SEC |
| Q1 2025 | May 7, 2025 | −$1.09 | −$1.13 | −3.60% | $0.00 | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.99 | −$1.12 | −13.61% | $0.00 | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.89 | −$0.94 | −5.24% | $0.00 | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.77 | −$0.81 | −4.56% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$0.75 | −$0.70 | +6.20% | $0.00 | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.85 | −$1.14 | −33.66% | $742,000.00 | SEC |
| Q3 2023 | Nov 6, 2023 | −$1.01 | −$0.99 | +2.05% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.82 | −$0.92 | −11.80% | $3.8M | SEC |
| Q1 2023 | May 8, 2023 | −$0.80 | −$0.72 | +10.35% | $7.0M | SEC |
| Q4 2022 | Feb 27, 2023 | −$0.82 | −$0.63 | +23.36% | $15.3M | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.84 | −$0.87 | −3.35% | $3.4M | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.85 | −$0.82 | +3.53% | $9.1M | SEC |
| Q1 2022 | May 9, 2022 | −$0.78 | −$0.78 | −0.65% | $7.6M | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.64 | −$0.71 | −11.18% | $9.5M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.63 | −$0.72 | −15.07% | $1.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Revolution Medicines (RVMD) last report earnings?
Revolution Medicines last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did RVMD beat earnings estimates?
No. Revolution Medicines reported EPS of −$3.06 for Q2 2026 against a −$2.04 estimate — a 49.81% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.